Tag: ocrelizumab
Solicitud de la MSIF para la Lista de Medicamentos Esenciales
Efforts to improve access to MS treatments continue
Aprobado en Europa el primer tratamiento para la EM primaria progresiva
The European Commission has approved the first disease-modifying therapy, ocrelizumab, for early primary progressive MS (PPMS).
European Medicines Agency recommends market authorisation for ocrelizumab (Ocrevus) in EU
The EMA has recommended that ocrelizumab (Ocrevus), the first disease-modifying treatment for primary progressive MS (PPMS), be prescribed for adults with early primary progressive MS
Primer tratamiento autorizado para la EM progresiva primaria en los EE. UU.
Ocrelizumab has been approved as a treatment for both relapsing and primary progressive MS in the US
Lo más destacado en investigación de 2016
Professor Alan Thompson highlights some of 2016’s research discoveries in MS